Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- May 15 2004
- Volume 11
- Issue 9
Did You Know…
Advertisement
(NY Daily News, 2004)
$247,500—Annual compensation for James Hoffa, president of the Teamsters Union.
(NY Daily News, 2004)
$241,989—Annual compensation for John Sweeney, president of the American Federation of Labor-Congress of Industrial Unions.
(NY Daily News, 2004)
$750,000—Compensation for Harrison Ford to appear in the 1977 movie Star Wars.
(NY Daily News, 2004)
$25 million—Current asking price for Harrison Ford to appear in a movie.
(NY Daily News, 2004)
$75,000—Compensation for Tom Cruise to appear in the 1983 movie Risky Business.
(NY Daily News, 2004)
$25 million—Current asking price for Tom Cruise to appear in a movie.
(NY Daily News, 2004)
$50,000—Compensation for Julia Roberts to appear in the 1988 movie Mystic Pizza.
(NY Daily News, 2004)
$25 million—Current asking price for Julia Roberts to appear in a movie.
(Time, 2004)
$103 million—Average cost to produce and market a major motion picture.
(BusinessWeek, 2004)
600,000—Number of movie copies illegally downloaded from the Internet each day.
Articles in this issue
about 18 years ago
Examine the Current Recruitment Trendsabout 18 years ago
Teach Your Kids Priceless Money Lessonsabout 18 years ago
Recognize a Suitable Employment Offerabout 18 years ago
Grasp the Shaky Economics of Medicineabout 18 years ago
Choose Between a Big Hat or Big Cattleabout 18 years ago
Safeguard Your Assets with Solid Trustsabout 18 years ago
Medicare Payments Under a Cloudabout 18 years ago
Doc Execs Rake It Inabout 18 years ago
Residents: Students or Employees?about 18 years ago
Careful on Medicare ChargesAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5